PMV Pharmaceuticals (PMVP) Financials

PMV Pharmaceuticals logo
$1.22 0.00 (0.00%)
Closing price 04:00 PM Eastern
Extended Trading
$1.25 +0.03 (+2.05%)
As of 05:41 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Annual Income Statements for PMV Pharmaceuticals

Annual Income Statements for PMV Pharmaceuticals

This table shows PMV Pharmaceuticals' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders
-18 -25 -34 -58 -73 -69 -59 -78
Consolidated Net Income / (Loss)
-18 -25 -34 -58 -73 -69 -59 -78
Net Income / (Loss) Continuing Operations
-18 -25 -34 -58 -73 -69 -59 -78
Total Pre-Tax Income
-18 -25 -34 -58 -73 -69 -75 -80
Total Operating Income
-19 -27 -35 -58 -77 -80 -85 -86
Total Gross Profit
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Revenue
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Cost of Revenue
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses
19 27 35 58 77 80 85 86
Selling, General & Admin Expense
5.04 5.88 11 22 25 24 27 16
Research & Development Expense
14 21 24 36 52 56 59 70
Total Other Income / (Expense), net
1.36 1.29 0.51 0.92 3.71 11 11 6.34
Interest Expense
-1.34 -1.30 -0.65 -0.45 -3.63 -11 -11 -6.34
Income Tax Expense
0.00 0.01 0.01 0.02 -0.01 0.00 -16 -2.17
Basic Earnings per Share
($5.82) ($8.35) ($2.40) ($1.28) ($1.61) ($1.44) ($1.14) ($1.48)
Weighted Average Basic Shares Outstanding
3.01M 3.04M 14.36M 45.14M 45.59M 48.01M 51.58M 52.54M
Diluted Earnings per Share
($5.82) ($8.35) ($2.40) ($1.28) ($1.61) ($1.44) ($1.14) ($1.48)
Weighted Average Diluted Shares Outstanding
3.01M 3.04M 14.36M 45.14M 45.59M 48.01M 51.58M 52.54M
Weighted Average Basic & Diluted Shares Outstanding
3.01M 3.04M 14.36M 45.14M 45.77M 51.44M 51.93M 53.33M

Quarterly Income Statements for PMV Pharmaceuticals

This table shows PMV Pharmaceuticals' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
Net Income / (Loss) Attributable to Common Shareholders
-15 -1.21 -19 -23 -17 -21 -21 -18 -18 -18 -34
Consolidated Net Income / (Loss)
-15 -1.21 -19 -23 -17 -21 -21 -18 -18 -18 -34
Net Income / (Loss) Continuing Operations
-15 -1.21 -19 -23 -17 -21 -21 -18 -18 -18 -34
Total Pre-Tax Income
-15 -17 -19 -23 -20 -21 -21 -18 -18 -18 -34
Total Operating Income
-18 -20 -22 -25 -22 -23 -23 -19 -19 -19 -20
Total Gross Profit
0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00
Total Revenue
0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00
Total Cost of Revenue
0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00
Total Operating Expenses
18 20 22 25 22 23 23 19 19 19 20
Selling, General & Admin Expense
5.04 5.54 4.94 11 4.12 4.48 4.31 3.42 3.69 4.21 4.00
Research & Development Expense
13 15 17 14 17 18 18 16 15 15 16
Total Other Income / (Expense), net
2.95 2.78 2.74 2.15 1.94 1.67 1.48 1.28 0.98 0.80 -14
Interest Expense
-2.95 -2.80 -2.62 -2.29 -1.94 -1.69 -1.48 -1.23 -0.98 -0.79 -0.83
Other Income / (Expense), net
-0.00 -0.02 0.12 - - -0.02 0.00 - - 0.01 -15
Income Tax Expense
0.00 -16 0.07 -0.00 -2.20 0.01 -0.01 0.03 0.00 0.00 -0.01
Basic Earnings per Share
($0.30) ($0.02) ($0.37) ($0.45) ($0.34) ($0.41) ($0.40) ($0.33) ($0.34) ($0.34) ($0.52)
Weighted Average Basic Shares Outstanding
51.45M 51.48M 51.57M 51.58M 51.95M 52.01M 52.99M 52.54M 53.33M 53.39M 66.23M
Diluted Earnings per Share
($0.30) ($0.02) ($0.37) ($0.45) ($0.34) ($0.41) ($0.40) ($0.33) ($0.34) ($0.34) ($0.52)
Weighted Average Diluted Shares Outstanding
51.45M 51.48M 51.57M 51.58M 51.95M 52.01M 52.99M 52.54M 53.33M 53.39M 66.23M
Weighted Average Basic & Diluted Shares Outstanding
51.44M 51.52M 51.75M 51.93M 51.95M 52.99M 53.21M 53.33M 53.33M 53.46M 75.53M

Annual Cash Flow Statements for PMV Pharmaceuticals

This table details how cash moves in and out of PMV Pharmaceuticals' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents
6.52 43 288 -188 -64 -71 2.35 -2.89
Net Cash From Operating Activities
-15 -22 -33 -47 -64 -56 -51 -74
Net Cash From Continuing Operating Activities
-15 -22 -33 -47 -64 -56 -51 -74
Net Income / (Loss) Continuing Operations
-18 -25 -34 -58 -73 -69 -59 -78
Consolidated Net Income / (Loss)
-18 -25 -34 -58 -73 -69 -59 -78
Depreciation Expense
0.34 0.39 0.32 0.31 0.32 1.26 1.14 0.13
Amortization Expense
0.32 0.06 0.15 0.55 -0.63 -5.39 -5.37 -2.77
Non-Cash Adjustments To Reconcile Net Income
1.07 0.92 2.08 6.30 10 12 13 5.89
Changes in Operating Assets and Liabilities, net
0.64 1.92 -0.85 4.12 -0.57 5.43 -1.59 0.91
Net Cash From Investing Activities
22 3.23 28 -144 -1.37 -51 53 70
Net Cash From Continuing Investing Activities
22 3.23 28 -145 -1.37 -51 53 70
Purchase of Property, Plant & Equipment
-0.45 -0.11 -0.15 -2.74 -7.98 -0.97 -0.66 -0.03
Purchase of Investments
-49 -43 -15 -257 -229 -221 -148 -88
Sale of Property, Plant & Equipment
- - - - 0.00 0.00 0.25 0.03
Sale and/or Maturity of Investments
71 47 43 115 236 171 202 158
Net Cash From Financing Activities
0.00 62 293 2.02 0.96 36 0.31 0.51
Net Cash From Continuing Financing Activities
0.00 62 293 2.02 0.96 36 0.31 0.51
Issuance of Preferred Equity
0.00 62 70 0.00 0.00 0.00 0.00 0.00
Issuance of Common Equity
0.00 0.00 223 2.02 0.96 36 0.31 0.51
Effect of Exchange Rate Changes
- - - 0.00 0.00 0.03 -0.04 0.01
Cash Income Taxes Paid
0.00 0.01 0.01 0.02 0.00 0.00 0.00 0.00

Quarterly Cash Flow Statements for PMV Pharmaceuticals

This table details how cash moves in and out of PMV Pharmaceuticals' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
Net Change in Cash & Equivalents
9.95 0.87 0.28 -8.76 10 -7.21 -7.79 1.65 1.15 -27 7.53
Net Cash From Operating Activities
-16 -1.60 -17 -17 -18 -18 -20 -17 -20 -15 -18
Net Cash From Continuing Operating Activities
-16 -1.60 -17 -16 -18 -18 -20 -17 -20 -15 -18
Net Income / (Loss) Continuing Operations
-15 -1.21 -19 -23 -17 -21 -21 -18 -18 -18 -34
Consolidated Net Income / (Loss)
-15 -1.21 -19 -23 -17 -21 -21 -18 -18 -18 -34
Depreciation Expense
0.36 0.37 0.37 0.04 0.04 0.03 0.03 0.03 0.03 0.02 0.02
Amortization Expense
-1.63 -1.38 -1.24 -1.13 -0.84 -0.72 -0.69 -0.51 -0.39 -0.38 -0.43
Non-Cash Adjustments To Reconcile Net Income
2.53 2.67 2.07 6.24 1.51 1.69 1.39 1.31 1.37 1.56 17
Changes in Operating Assets and Liabilities, net
-2.17 -2.05 1.18 1.45 -1.54 1.91 0.52 0.01 -2.66 2.30 -0.13
Net Cash From Investing Activities
26 2.32 17 7.74 29 11 12 18 21 -12 -21
Net Cash From Continuing Investing Activities
26 2.33 17 7.74 29 11 12 18 21 -12 -21
Purchase of Investments
-30 -41 -39 -38 -16 -31 -20 -21 -11 -27 -41
Sale of Property, Plant & Equipment
- - 0.03 0.22 - - 0.00 - - - 0.00
Sale and/or Maturity of Investments
57 43 56 45 44 42 32 40 32 15 20
Net Cash From Financing Activities
0.00 0.14 - 0.17 0.01 0.10 - 0.39 0.00 0.14 47
Net Cash From Continuing Financing Activities
0.00 0.14 - 0.17 0.01 0.10 - 0.39 0.00 0.14 47
Issuance of Common Equity
- - - 0.17 - - - 0.39 - - 51
Effect of Exchange Rate Changes
-0.03 0.01 0.00 -0.01 0.01 -0.00 0.00 -0.00 0.00 - 0.00

Annual Balance Sheets for PMV Pharmaceuticals

This table presents PMV Pharmaceuticals' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets
103 366 332 270 252 191 117
Total Current Assets
102 365 301 247 207 176 115
Cash & Equivalents
73 361 172 108 38 41 38
Short-Term Investments
28 0.00 125 133 165 129 75
Prepaid Expenses
0.61 3.34 3.30 5.13 3.53 6.20 2.28
Plant, Property, & Equipment, net
0.74 0.57 3.09 11 11 0.41 0.24
Total Noncurrent Assets
0.20 0.20 27 12 34 15 1.10
Long-Term Investments
- 0.00 17 2.50 26 14 0.00
Other Noncurrent Operating Assets
0.20 0.20 10 9.85 8.57 1.38 1.10
Total Liabilities & Shareholders' Equity
103 366 332 270 252 191 117
Total Liabilities
4.57 6.41 23 24 26 15 12
Total Current Liabilities
4.52 6.41 12 11 14 14 11
Accounts Payable
2.84 1.61 3.19 3.00 3.24 6.58 3.16
Accrued Expenses
1.69 4.80 8.63 7.31 9.94 7.44 7.86
Other Current Liabilities
- 0.00 0.40 0.53 0.85 0.35 0.40
Total Noncurrent Liabilities
0.05 0.00 11 13 12 0.84 0.44
Other Noncurrent Operating Liabilities
0.05 0.00 11 13 12 0.84 0.44
Total Equity & Noncontrolling Interests
-70 359 309 246 226 176 105
Total Preferred & Common Equity
-70 359 309 246 226 176 105
Preferred Stock
0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity
-70 359 309 246 226 176 105
Common Stock
4.97 469 476 488 535 545 551
Retained Earnings
-75 -110 -168 -241 -310 -369 -446
Accumulated Other Comprehensive Income / (Loss)
-0.00 0.00 -0.08 -0.45 0.22 0.14 0.08

Quarterly Balance Sheets for PMV Pharmaceuticals

This table presents PMV Pharmaceuticals' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026 6/30/2026 9/30/2026
Total Assets
261 237 238 223 171 153 134 97 82 111
Total Current Assets
205 202 219 190 163 145 132 96 81 105
Cash & Equivalents
52 48 49 49 51 44 36 39 12 20
Short-Term Investments
150 150 164 134 109 98 93 54 67 83
Prepaid Expenses
2.56 3.70 5.05 5.96 3.11 3.04 3.20 2.23 1.98 2.33
Plant, Property, & Equipment, net
11 11 11 10 0.38 0.29 0.26 0.20 0.15 0.13
Total Noncurrent Assets
45 24 8.22 24 6.73 7.26 1.14 0.58 0.51 6.38
Long-Term Investments
36 15 0.00 15 5.44 6.03 0.00 - - 5.96
Other Noncurrent Operating Assets
8.73 8.39 8.22 8.65 1.30 1.23 1.14 0.58 0.51 0.42
Total Liabilities & Shareholders' Equity
261 237 238 223 171 153 134 97 82 111
Total Liabilities
23 24 23 26 11 12 13 8.60 11 54
Total Current Liabilities
11 12 11 14 9.76 12 12 8.60 11 11
Accounts Payable
1.68 0.86 4.53 2.06 3.59 2.60 3.40 1.63 2.02 1.64
Accrued Expenses
9.04 10 5.70 10 5.80 8.63 8.52 6.67 8.33 8.91
Other Current Liabilities
0.00 0.88 1.15 1.24 0.36 0.38 0.39 0.29 0.22 0.14
Total Noncurrent Liabilities
13 12 12 12 0.74 0.64 0.54 0.00 0.00 44
Other Noncurrent Operating Liabilities
13 12 12 12 0.74 0.64 0.54 0.00 0.00 44
Total Equity & Noncontrolling Interests
238 213 214 198 160 141 121 88 72 57
Total Preferred & Common Equity
238 213 214 198 160 141 121 88 72 57
Preferred Stock
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity
238 213 214 198 160 141 121 88 72 57
Common Stock
532 538 541 543 546 548 549 552 554 574
Retained Earnings
-294 -325 -326 -346 -386 -407 -428 -464 -483 -517
Accumulated Other Comprehensive Income / (Loss)
-0.36 -0.13 -0.19 0.41 0.08 0.02 0.09 -0.02 -0.08 -0.16

Annual Metrics And Ratios for PMV Pharmaceuticals

This table displays calculated financial ratios and metrics derived from PMV Pharmaceuticals' official financial filings.

Metric 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding
0.00 0.00 44,773,748.00 45,380,354.00 45,665,428.00 51,157,636.00 - 53,211,507.00
DEI Adjusted Shares Outstanding
0.00 0.00 44,773,748.00 45,380,354.00 45,665,428.00 51,157,636.00 - 53,211,507.00
DEI Earnings Per Adjusted Shares Outstanding
0.00 0.00 -0.77 -1.27 -1.61 -1.35 - -1.46
Growth Metrics
- - - - - - - -
Revenue Growth
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth
0.00% -43.78% -32.14% -64.57% -35.64% -9.05% -6.45% 0.93%
EBIT Growth
0.00% -41.16% -31.68% -64.81% -33.08% -4.13% -6.66% -0.89%
NOPAT Growth
0.00% -41.00% -31.18% -66.83% -32.16% -4.01% -6.63% -0.89%
Net Income Growth
0.00% -44.55% -35.85% -67.96% -26.75% 5.94% 14.87% -32.42%
EPS Growth
0.00% -43.47% 71.26% 46.67% -25.78% 10.56% 20.83% -29.82%
Operating Cash Flow Growth
0.00% -45.37% -48.38% -42.25% -36.91% 12.71% 7.86% -43.48%
Free Cash Flow Firm Growth
0.00% 0.00% -61.25% -45.99% -68.41% 18.06% -10.94% -5.40%
Invested Capital Growth
0.00% 0.00% 23.98% -175.40% 126.15% -322.99% -95.32% -14.05%
Revenue Q/Q Growth
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth
0.00% 0.00% 0.00% -15.19% -4.77% 1.40% -6.99% 7.02%
EBIT Q/Q Growth
0.00% 0.00% 0.00% -15.17% -3.91% 2.74% -7.94% 6.60%
NOPAT Q/Q Growth
0.00% 0.00% 0.00% -15.84% -3.62% 2.74% -7.91% 6.43%
Net Income Q/Q Growth
0.00% 0.00% 0.00% -15.83% -1.36% 4.95% -14.08% 6.00%
EPS Q/Q Growth
0.00% 0.00% 0.00% -140.25% -1.26% 7.69% -15.15% 7.50%
Operating Cash Flow Q/Q Growth
0.00% 0.00% -18.82% -3.83% -5.45% 5.50% -9.80% -0.72%
Free Cash Flow Firm Q/Q Growth
0.00% 0.00% 0.00% 0.00% -11.20% 7.49% -0.72% -3.92%
Invested Capital Q/Q Growth
0.00% 0.00% 0.00% -198.07% 9.45% -181.63% -748.06% 0.24%
Profitability Metrics
- - - - - - - -
Gross Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent
100.02% 100.03% 100.02% 100.04% 99.99% 100.00% 78.48% 97.28%
Interest Burden Percent
92.90% 95.12% 98.14% 100.00% 95.29% 86.06% 87.53% 92.70%
Effective Tax Rate
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)
0.00% -25.75% -15.05% -17.33% -26.44% -29.24% -29.23% -55.37%
Cash Return on Invested Capital (CROIC)
0.00% 0.00% 0.00% 0.00% -3,736.99% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)
0.00% 18.43% -9.50% -17.33% -26.44% -29.24% -29.23% -55.37%
Return on Equity Simple (ROE_SIMPLE)
0.00% 35.97% -9.59% -18.75% -29.80% 0.00% -33.34% 0.00%
Net Operating Profit after Tax (NOPAT)
-13 -19 -24 -41 -54 -56 -60 -60
NOPAT Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)
0.00% -13.22% -4.31% -5.04% -6.93% -5.43% 0.54% -11.75%
Return On Investment Capital (ROIC_SIMPLE)
- - - - -21.92% -24.85% -33.97% -57.63%
Cost of Revenue to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)
-19 -27 -35 -58 -77 -80 -85 -86
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
-18 -26 -35 -57 -77 -84 -90 -89
Valuation Ratios
- - - - - - - -
Price to Book Value (P/BV)
0.00 0.00 7.67 3.40 1.61 0.70 0.44 0.64
Price to Tangible Book Value (P/TBV)
0.00 0.00 7.67 3.40 1.61 0.70 0.44 0.64
Price to Revenue (P/Rev)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)
0.00 0.00 0.00 0.00 92.29 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency
- - - - - - - -
Debt to Equity
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage
0.00 -1.03 -1.01 -1.01 -1.01 -1.00 -1.03 -1.06
Leverage Ratio
0.00 1.05 1.02 1.04 1.09 1.11 1.10 1.10
Compound Leverage Factor
0.00 1.00 1.01 1.04 1.03 0.95 0.97 1.02
Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 171.58% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital
0.00% -71.58% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score
0.00 27.04 258.23 27.10 8.68 1.75 -0.08 -3.37
Noncontrolling Interest Sharing Ratio
0.00% 171.58% 36.92% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios
- - - - - - - -
Current Ratio
0.00 22.57 56.91 24.66 22.80 14.78 12.22 10.09
Quick Ratio
0.00 22.44 56.38 24.32 22.25 14.47 11.79 9.89
Cash Flow Metrics
- - - - - - - -
Free Cash Flow to Firm (FCFF)
0.00 -16 -25 -37 -62 -51 -56 -59
Operating Cash Flow to CapEx
-3,357.96% -20,243.12% -22,120.95% -1,699.67% -798.60% -5,749.69% -12,693.56% 0.00%
Free Cash Flow to Firm to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios
- - - - - - - -
Asset Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics
- - - - - - - -
Invested Capital
0.00 -3.03 -2.30 -6.34 1.66 -3.70 -7.22 -8.23
Invested Capital Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital
0.00 -3.03 0.73 -4.04 7.99 -5.35 -3.52 -1.01
Enterprise Value (EV)
0.00 279 2,393 733 153 -71 -105 -46
Market Capitalization
212 212 2,754 1,048 397 159 78 67
Book Value per Share
$0.00 ($23.22) $8.02 $6.80 $5.39 $4.41 $3.40 $1.97
Tangible Book Value per Share
$0.00 ($23.22) $8.02 $6.80 $5.39 $4.41 $3.40 $1.97
Total Capital
0.00 98 359 309 246 226 176 105
Total Debt
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt
0.00 -101 -361 -315 -244 -229 -183 -113
Capital Expenditures (CapEx)
0.45 0.11 0.15 2.74 7.98 0.97 0.40 -0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)
0.00 -3.92 -3.07 -8.92 -5.70 -10 -8.17 -9.13
Debt-free Net Working Capital (DFNWC)
0.00 98 358 289 236 193 161 104
Net Working Capital (NWC)
0.00 98 358 289 236 193 161 104
Net Nonoperating Expense (NNE)
4.31 6.71 9.98 17 19 13 -1.10 17
Net Nonoperating Obligations (NNO)
0.00 -101 -361 -315 -244 -229 -183 -113
Total Depreciation and Amortization (D&A)
0.66 0.45 0.47 0.86 -0.31 -4.13 -4.23 -2.64
Debt-free, Cash-free Net Working Capital to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments
- - - - - - - -
Adjusted Basic Earnings per Share
$0.00 $0.00 ($2.40) ($1.28) ($1.61) ($1.44) ($1.14) ($1.48)
Adjusted Weighted Average Basic Shares Outstanding
0.00 0.00 44.78M 45.45M 45.59M 48.01M 51.58M 52.54M
Adjusted Diluted Earnings per Share
$0.00 $0.00 ($2.40) ($1.28) ($1.61) ($1.44) ($1.14) ($1.48)
Adjusted Weighted Average Diluted Shares Outstanding
0.00 0.00 44.78M 45.45M 45.59M 48.01M 51.58M 52.54M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 ($2.40) ($1.28) $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
0.00 0.00 14.36M 45.14M 45.77M 51.44M 51.93M 53.33M
Normalized Net Operating Profit after Tax (NOPAT)
-13 -19 -24 -41 -54 -56 -60 -60
Normalized NOPAT Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios
- - - - - - - -
EBIT to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios
- - - - - - - -
Dividend Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for PMV Pharmaceuticals

This table displays calculated financial ratios and metrics derived from PMV Pharmaceuticals' official financial filings.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
DEI Shares Outstanding
51,443,488.00 51,443,488.00 51,519,751.00 - 51,933,604.00 51,952,680.00 52,990,864.00 53,211,507.00 53,329,392.00 53,331,766.00 53,458,058.00
DEI Adjusted Shares Outstanding
51,443,488.00 51,443,488.00 51,519,751.00 - 51,933,604.00 51,952,680.00 52,990,864.00 53,211,507.00 53,329,392.00 53,331,766.00 53,458,058.00
DEI Earnings Per Adjusted Shares Outstanding
-0.30 -0.02 -0.37 - -0.34 -0.41 -0.40 -0.34 -0.34 -0.34 -0.64
Growth Metrics
- - - - - - - - - - -
Revenue Growth
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth
11.39% -2.32% -7.22% -28.62% -14.77% -11.31% -2.55% 24.91% 13.40% 18.48% -53.63%
EBIT Growth
15.06% -0.32% -10.92% -33.16% -18.34% -13.41% -3.57% 23.55% 11.80% 17.58% -56.33%
NOPAT Growth
15.17% -0.24% -11.51% -33.16% -18.35% -13.43% -2.90% 23.55% 11.80% 17.47% 10.92%
Net Income Growth
20.17% 93.04% -15.54% -45.98% -14.18% -1,648.56% -9.53% 21.58% -3.45% 14.73% -63.22%
EPS Growth
28.57% 94.74% -8.82% -50.00% -13.33% -1,950.00% -8.11% 26.67% 0.00% 17.07% -30.00%
Operating Cash Flow Growth
-7.81% 87.61% -7.54% -37.87% -12.86% -1,045.31% -17.70% -3.17% -7.74% 20.35% 8.25%
Free Cash Flow Firm Growth
38.50% -22.46% -44.61% -78.90% 8.36% 53.23% 47.00% 11.65% -27.06% -67.78% 448.00%
Invested Capital Growth
0.00% 130.91% 35.14% -95.32% -374.36% -1,441.64% -869.57% -14.05% 2.34% -2.99% -523.04%
Revenue Q/Q Growth
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth
4.55% -8.74% -6.80% -16.04% 14.83% -5.44% 1.61% 15.03% 1.78% 0.73% -85.24%
EBIT Q/Q Growth
3.60% -10.78% -7.83% -15.63% 14.32% -6.15% 1.53% 14.66% 1.15% 0.78% -86.58%
NOPAT Q/Q Growth
3.60% -10.70% -8.52% -14.99% 14.32% -6.10% 1.56% 14.57% 1.15% 0.73% -6.26%
Net Income Q/Q Growth
3.08% 92.06% -1,485.00% -19.63% 24.19% -21.64% 0.71% 14.35% -0.01% -0.27% -90.05%
EPS Q/Q Growth
0.00% 93.33% -1,750.00% -21.62% 24.44% -20.59% 2.44% 17.50% -3.03% 0.00% -52.94%
Operating Cash Flow Q/Q Growth
-33.92% 90.13% -953.75% 1.06% -9.63% -0.20% -8.29% 13.27% -14.49% 25.93% -24.74%
Free Cash Flow Firm Q/Q Growth
-46.58% -43.29% 4.64% 10.68% 24.92% 26.87% -8.08% -48.88% -7.97% 3.43% 324.17%
Invested Capital Q/Q Growth
67.39% 147.63% -248.26% -748.06% 20.80% -34.73% -7.14% 0.24% 32.18% -42.08% -548.18%
Profitability Metrics
- - - - - - - - - - -
Gross Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent
100.00% 6.98% 100.39% 100.00% 88.81% 100.02% 99.97% 100.14% 100.00% 100.02% 99.98%
Interest Burden Percent
83.80% 86.12% 87.99% 91.39% 91.05% 92.62% 93.44% 93.61% 94.84% 95.82% 97.64%
Effective Tax Rate
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)
-30.61% -22.62% -23.63% -29.23% -32.66% -45.57% -51.87% -55.37% -63.16% -70.93% -99.42%
Cash Return on Invested Capital (CROIC)
0.00% -9,804.13% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)
-30.61% -22.62% -23.63% -29.23% -32.66% -45.57% -51.87% -55.37% -63.16% -70.93% -99.42%
Return on Equity Simple (ROE_SIMPLE)
-30.61% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)
-13 -14 -15 -18 -15 -16 -16 -13 -13 -13 -14
NOPAT Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)
-2.35% 5.96% -1.78% -2.61% -1.23% -2.87% -3.23% -3.08% -3.64% -4.28% -17.10%
Return On Investment Capital (ROIC_SIMPLE)
-6.00% -6.59% -7.74% -10.01% -9.43% -11.39% -13.03% -12.86% -15.13% -18.48% -24.59%
Cost of Revenue to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)
-18 -20 -22 -25 -22 -23 -23 -19 -19 -19 -35
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
-19 -21 -23 -26 -22 -24 -23 -20 -19 -19 -36
Valuation Ratios
- - - - - - - - - - -
Price to Book Value (P/BV)
0.41 0.39 0.39 0.44 0.35 0.39 0.61 0.64 0.75 1.00 1.56
Price to Tangible Book Value (P/TBV)
0.41 0.39 0.39 0.44 0.35 0.39 0.61 0.64 0.75 1.00 1.56
Price to Revenue (P/Rev)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency
- - - - - - - - - - -
Debt to Equity
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage
-1.01 -1.00 -1.01 -1.03 -1.02 -1.02 -1.03 -1.06 -1.05 -1.07 -1.34
Leverage Ratio
1.11 1.11 1.11 1.10 1.09 1.10 1.12 1.10 1.08 1.11 1.38
Compound Leverage Factor
0.93 0.96 0.98 1.01 1.00 1.02 1.05 1.03 1.02 1.06 1.34
Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital
100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score
0.96 1.00 0.26 0.96 0.73 -0.48 -0.49 -1.47 -1.68 -3.90 -5.54
Noncontrolling Interest Sharing Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios
- - - - - - - - - - -
Current Ratio
16.79 19.22 13.98 12.22 16.75 12.52 10.76 10.09 11.14 7.70 9.81
Quick Ratio
16.42 18.70 13.48 11.79 16.43 12.26 10.50 9.89 10.88 7.52 9.59
Cash Flow Metrics
- - - - - - - - - - -
Free Cash Flow to Firm (FCFF)
-12 -17 -16 -14 -11 -7.74 -8.37 -12 -13 -13 29
Operating Cash Flow to CapEx
-2,697.33% 0.00% 0.00% 0.00% -456,650.00% -166,381.82% 0.00% -114,593.33% 0.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios
- - - - - - - - - - -
Asset Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics
- - - - - - - - - - -
Invested Capital
-1.21 0.57 -0.85 -7.22 -5.72 -7.70 -8.25 -8.23 -5.58 -7.93 -51
Invested Capital Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital
-1.21 2.43 0.46 -3.52 -4.51 -8.28 -7.40 -1.01 0.13 -0.23 -43
Enterprise Value (EV)
-126 -130 -122 -105 -109 -93 -55 -46 -27 -7.97 -19
Market Capitalization
87 83 77 78 57 55 74 67 66 71 89
Book Value per Share
$4.13 $4.17 $3.84 $3.40 $3.08 $2.71 $2.28 $1.97 $1.65 $1.34 $1.07
Tangible Book Value per Share
$4.13 $4.17 $3.84 $3.40 $3.08 $2.71 $2.28 $1.97 $1.65 $1.34 $1.07
Total Capital
213 214 198 176 160 141 121 105 88 72 57
Total Debt
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt
-214 -214 -199 -183 -166 -148 -129 -113 -94 -79 -109
Capital Expenditures (CapEx)
0.60 -0.00 -0.03 -0.17 0.00 0.01 -0.00 0.02 0.00 0.00 -0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)
-8.36 -6.34 -7.61 -8.17 -6.65 -8.57 -9.11 -9.13 -6.36 -8.59 -8.36
Debt-free Net Working Capital (DFNWC)
190 207 176 161 154 134 120 104 87 71 94
Net Working Capital (NWC)
190 207 176 161 154 134 120 104 87 71 94
Net Nonoperating Expense (NNE)
2.52 -13 3.90 5.38 2.34 5.19 5.29 4.57 4.72 4.87 20
Net Nonoperating Obligations (NNO)
-214 -214 -199 -183 -166 -148 -129 -113 -94 -79 -109
Total Depreciation and Amortization (D&A)
-1.27 -1.00 -0.86 -1.09 -0.80 -0.69 -0.66 -0.48 -0.35 -0.36 -0.41
Debt-free, Cash-free Net Working Capital to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments
- - - - - - - - - - -
Adjusted Basic Earnings per Share
($0.30) ($0.02) ($0.37) ($0.45) ($0.34) ($0.41) ($0.40) ($0.33) ($0.34) ($0.34) ($0.52)
Adjusted Weighted Average Basic Shares Outstanding
51.45M 51.48M 51.57M 51.58M 51.95M 52.01M 52.99M 52.54M 53.33M 53.39M 66.23M
Adjusted Diluted Earnings per Share
($0.30) ($0.02) ($0.37) ($0.45) ($0.34) ($0.41) ($0.40) ($0.33) ($0.34) ($0.34) ($0.52)
Adjusted Weighted Average Diluted Shares Outstanding
51.45M 51.48M 51.57M 51.58M 51.95M 52.01M 52.99M 52.54M 53.33M 53.39M 66.23M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
51.44M 51.52M 51.75M 51.93M 51.95M 52.99M 53.21M 53.33M 53.33M 53.46M 75.53M
Normalized Net Operating Profit after Tax (NOPAT)
-13 -14 -15 -18 -15 -16 -16 -13 -13 -13 -14
Normalized NOPAT Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios
- - - - - - - - - - -
EBIT to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios
- - - - - - - - - - -
Dividend Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

PMV Pharmaceuticals remains a development-stage company with no reported revenue across the periods provided. Q2 2026 revenue and gross profit were both zero, while the company recorded an operating loss of $18.9 million and a net loss of $18.1 million, or $0.34 per diluted share. Losses have remained persistent, ranging from approximately $15.3 million to $23.0 million per quarter since Q1 2024.

There was some improvement in spending during Q2 2026. Total operating expenses declined to $18.9 million from $22.9 million in Q2 2025, primarily because research and development expense fell to $14.7 million from $18.4 million. Selling, general and administrative expense also declined modestly year over year. However, the lower spending has not yet produced revenue or reduced the company’s underlying cash burn.

Liquidity has weakened materially over the longer period. Cash and short-term investments totaled approximately $79.4 million at June 30, 2026, down from roughly $212.9 million at June 30, 2024 and $202.7 million at September 30, 2023. Q2 2026 operating cash flow was negative $14.6 million. Based on the first two quarters of 2026, operating cash use averaged about $17.1 million per quarter, suggesting that the current liquid asset balance could fund roughly four to five quarters of operations before additional financing may be needed, assuming the burn rate remains similar.

The balance sheet remains lightly leveraged, but shareholder equity is shrinking. PMV reported $10.6 million of total liabilities and no noncurrent liabilities in Q2 2026, against $71.5 million of equity. Nevertheless, retained earnings have deteriorated to a deficit of $482.6 million, and weighted-average shares outstanding have risen from 51.5 million in Q2 2024 to 53.4 million in Q2 2026, indicating some dilution risk as losses continue.

  • Operating expenses are trending lower: Q2 2026 operating expenses of $18.9 million were down from $22.9 million in Q2 2025 and $20.2 million in Q2 2024.
  • Research spending has been reduced: Quarterly R&D expense declined to $14.7 million in Q2 2026 from $18.4 million a year earlier, which may extend the company’s cash runway if the reduction is sustainable.
  • Low leverage provides financial flexibility: Total liabilities were $10.6 million, with no noncurrent liabilities reported, limiting near-term debt obligations.
  • Current liquidity remains substantial relative to liabilities: Cash and short-term investments of approximately $79.4 million were about 7.5 times total liabilities at the end of Q2 2026.
  • Investment portfolio activity is driving cash fluctuations: PMV purchased $26.7 million of investments and received $14.5 million from sales or maturities in Q2 2026. These transactions affect reported cash changes but do not represent operating revenue.
  • Interest income and other investment-related income partially offset losses: Net other income was reported at $798,000 in Q2 2026, helping reduce the impact of operating expenses but not changing the company’s loss-making profile.
  • PMV continues to report no revenue: Revenue has been zero in each income statement period provided, leaving the company dependent on its cash and investment holdings.
  • Operating cash flow remains consistently negative: PMV used $14.6 million in operating cash during Q2 2026, following cash usage of $19.7 million in Q1 2026 and $18.3 million in Q2 2025.
  • Liquidity has declined sharply: Cash and short-term investments fell approximately 63% from June 2024 to June 2026, reducing the company’s ability to absorb continued research and development spending.
  • Continued losses may lead to future dilution: Retained earnings reached a deficit of $482.6 million, while weighted-average shares increased roughly 3.6% from Q2 2025 to Q2 2026. Additional equity financing could further dilute existing shareholders.
11/18/26 05:54 PM ETAI Generated. May Contain Errors.

PMV Pharmaceuticals Financials - Frequently Asked Questions

According to the most recent income statement we have on file, PMV Pharmaceuticals' fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

PMV Pharmaceuticals' net income appears to be on a downward trend, with a most recent value of -$77.74 million in 2025, falling from -$17.54 million in 2018. The previous period was -$58.71 million in 2024. See where experts think PMV Pharmaceuticals is headed by visiting PMV Pharmaceuticals' forecast page.

PMV Pharmaceuticals' total operating income in 2025 was -$86.21 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $86.21 million

Over the last 7 years, PMV Pharmaceuticals' total revenue changed from $0.00 in 2018 to $0.00 in 2025, a change of 0.0%.

In the past 12 quarters, PMV Pharmaceuticals' cash and equivalents has ranged from $12.47 million in Q2 2026 to $52.06 million in Q3 2023, and is currently $19.99 million as of their latest financial filing in Q3 2026.

PMV Pharmaceuticals had total debt of $0.00 at the end of 2025, compared with none in 2024, and none in 2018.

Over the last 7 years, PMV Pharmaceuticals' book value per share changed from 0.00 in 2018 to 1.97 in 2025, a change of 196.8%.



Financial statements for NASDAQ:PMVP last updated on 11/10/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners